GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
$2.55
+0.0800 (+3.24%)
At Close: Apr 19, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile
There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:
Click to get the best stock tips daily for free!

About Cellectis S.A.

Cellectis S.A. Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... CLLS Profile

Golden Star

Ticker Date Change Price
DOOR Apr 17 0.0305% $131.35
LNG Apr 17 3.29% $156.81
FCN Apr 16 1.75% $207.62
ELV Apr 16 4.82% $506.97
FTSL Apr 16 0.217% $46.08
AKR Apr 05 3.15% $16.53
ITCI Apr 05 5.74% $68.44
SARK Mar 28 18.79% $26.88
SON Mar 26 0.83% $56.64
ARCC Mar 25 2.34% $20.12
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT